Posted inNews and Updates
New Targeted Therapy Shows Promise for GNAQ/GNA11 Melanoma
New Phase 1 trial results reveal a novel inhibitor targeting GNAQ and GNA11-mutant melanomas, marking a major step forward in precision cancer therapy.
Posted inNews and Updates
Clinical Trial Disruptions: How CRO Mergers Impact Sites
Discover how mid-study CRO mergers create operational risks for clinical sites, from payment delays to staff turnover, and how to protect your trial data.
Posted inNews and Updates
Lecanemab Autoinjector Shows Bioequivalence to IV Infusion
New clinical data confirms lecanemab’s subcutaneous autoinjector is bioequivalent to IV infusion, promising a simpler treatment path for Alzheimer’s patients.
Posted inNews and Updates
Digital Twins in Clinical Trials: Innovation vs. Validation
Digital twins offer to revolutionize clinical trials, but regulatory validation challenges may hinder their progress. Explore the impact on medical research.
Posted inNews and Updates
FDA Raises Concerns Over Orviglance Clinical Data
The FDA has raised clinical objections regarding image-reading protocols for the liver contrast agent Orviglance. Learn what this means for the drug's future.
Posted inNews and Updates
Maharashtra FDA Halts Sale of Two Cadila Pharmaceuticals Drugs
Maharashtra FDA has banned two Cadila Pharmaceuticals drugs due to branding concerns. Learn how this regulatory move aims to prevent medication errors.
Posted inNews and Updates
FDA Clears Clinical Trial for Novel Peanut Allergy Drug LP-3
Longbio Pharma has received FDA clearance to begin clinical trials for LP-3, a potential new treatment targeting life-threatening peanut allergies.
Posted inNews and Updates
QAIAx Clinical Trial: Novel AGI-Driven Mental Health Care
The QAIAx clinical trial explores how AGI can support veteran mental health through alternative sentencing and VR-based pro-social dating programs.
Posted inNews and Updates
Leqembi Subcutaneous Injection: New Alzheimer’s Data Revealed
New trial data shows the Leqembi subcutaneous autoinjector offers similar efficacy to IV infusions, promising a more accessible future for Alzheimer’s care.
Posted inNews and Updates
Is BridgeBio Pharma Undervalued After Recent Clinical News?
Despite recent clinical setbacks for Wainua, analysts weigh in on BridgeBio Pharma’s potential. Is the biotech stock undervalued? Read the latest analysis.